Kuur Therapeutics is actively seeking licensing and partnering opportunities, drawing on global immunotherapy expertise, to explore and advance the therapeutic possibilities for our proprietary NKT cell immunotherapy products.
CAR-NKT Cell Platform
Our unique and proprietary lead technology platform harnesses CAR-NKT cells with potential for an off-the-shelf, allogeneic approach to cancer treatment.
Our first autologous product, targeting neuroblastoma, is currently actively recruiting in a first-in-human clinical trial and the clinical trial for our first off-the-shelf CAR-NKT product has been allowed to proceed by the FDA and will enter clinical trials in the first half of 2020, a significant milestone for the company and patients in need.
Virus Specific T Cells
In addition, our technology portfolio includes virus specific T cell (VST) products, for which we are actively seeking partnerships:
RapxCMV and CytovirADV proprietary VST cell treatments for viral infection reactivation following Hematopoietic Stem Cell Transplantation
RapxCMV and CytovirADV are naturally occurring VST cell products for the treatment of cytomegalovirus (CMV) or adenovirus (ADV) infection reactivation respectively, in hematopoietic stem cell transplant patients, which can be life-threatening complications and an area of significant unmet medical need. The results of the ASPIRE trial using CytovirADV have been published in the journal Cytotherapy.
To learn more about our partnering opportunities please contact us at: email@example.com
Our Academic Partner
Baylor College of Medicine
Kuur Therapeutics and the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership, signed in April 2016. Baylor is a world class center with significant expertise in cell and gene therapy across basic research, translational and clinical trials. CAGT at Baylor is led by the Founding Director, Malcolm K Brenner, MD, PhD, and the current Director Helen Heslop, MD, DSc (Hon), both of whom are leaders in the field of cell and gene therapy.
Our collaboration focuses on the development of our CAR-NKT platform through preclinical and clinical development. Leonid Metelitsa, MD, PhD is a world expert in NKT cells and has developed the pioneering CAR-NKT technology, a first-in-class innovative CAR cell therapy.
Our colleagues at CAGT and the Texas Children’s Hospital have initiated a phase 1 first-in-human study of autologous CAR-NKT therapy in patients with high-risk, relapsed, refractory neuroblastoma, led by Andras Heczey, MD. A second study in patients with relapsed, refractory B cell malignancy, evaluating an off-the-shelf CAR-NKT therapy, led by Carlos Ramos, MD, will begin at Baylor in the first half of 2020.
Kuur Therapeutics has exclusive rights to the CAR-NKT intellectual property generated at Baylor.